Ligand id: 6641

Name: rasagiline

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rasagiline

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 12.03
Molecular weight 171.1
XLogP 3.23
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used as an initial monotherapy in the early stages of Parkinson's disease and as an adjunctive to levodopa in the later stages of the disease.
Mechanism Of Action and Pharmacodynamic Effects
The exact mechanism of action of rasagiline is unknown, but is believed to relate to its inhibition of MAO-B leading to an increase in extracellular levels of dopamine in the striatum.
External links